Brief: Newbury Pharmaceuticals Adds Levodopa/Benserazide To Portfolio

Newbury Pharmaceuticals AB

22/09/2023 09:06

Sept 22 (Reuters) - Newbury Pharmaceuticals AB
 NEWBRY.ST :
    * NEWBURY PHARMACEUTICALS IS STRENGTHENING ITS PORTFOLIO
WITH
LEVODOPA/BENSERAZIDE
    * PLEASED TO ANNOUNCE SUCCESSFUL ENLARGEMENT OF PORTFOLIO
WITH
ADDITION OF LEVODOPA/BENSERAZIDE TABLETS
    * WE AIM TO LAUNCH THIS MEDICINE IN SWEDEN WHERE TOTAL
ANNUAL
VALUE OF MARKET IS ESTIMATED TO BE 4 MEUR ACCORDING TO DLMI
NORDIC PHARMA INSIGHTS

Source text for Eikon:  ID:nMFNbr1ZRd 
Further company coverage:  NEWBRY.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))